Metoklopramid-Hidroklorid Noridem

Metoclopramide Hydrochloride, the active ingredient in Metoklopramid-Hidroklorid Noridem, is a dopamine D2 receptor antagonist presented as a sterile injectable solution for intramuscular or intravenous use. It is employed to manage nausea, vomiting and gastric motility disorders in adult patients.

GNH USA supplies Metoklopramid-Hidroklorid Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Metoclopramide Hydrochloride acts on the gastrointestinal and central nervous systems to control emesis and improve gastric emptying.

- Post‑operative nausea and vomiting: reduces the frequency and severity of nausea after surgery. - Chemotherapy‑induced nausea and vomiting: helps prevent acute emesis associated with cytotoxic agents. - Gastroparesis: enhances gastric motility to alleviate delayed gastric emptying. - Gastro‑oesophageal reflux disease: facilitates lower oesophageal sphincter tone and gastric emptying. - Facilitation of gastric emptying before diagnostic procedures: improves tolerance of imaging studies requiring an empty stomach.

Metoclopramide Hydrochloride may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Drowsiness: mild sedation or fatigue. - Extrapyramidal symptoms: transient muscle rigidity or tremor. - Diarrhoea: increased bowel movements. - Restlessness: feeling of inner agitation. - Headache: mild to moderate intensity. - Hyperprolactinaemia: elevated prolactin leading to breast tenderness.

Serious or Rare Side Effects: - Tardive dyskinesia: persistent involuntary movements, especially with prolonged use. - Neuroleptic malignant syndrome: rare but life‑threatening hyperthermia and rigidity. - Severe allergic reaction: anaphylaxis, rash, or angioedema. - Cardiac arrhythmias: QT prolongation in susceptible individuals. - Depression or suicidal thoughts: mood changes requiring immediate evaluation.

Before initiating therapy, clinicians should assess patient history and monitor for specific risks.

- Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: consider possible excretion in milk and infant exposure. - Renal impairment: adjust dosing or monitor closely in patients with reduced clearance. - History of movement disorders: avoid or use with caution in patients with Parkinson’s disease or dystonia. - Concomitant CNS depressants: monitor for additive sedation. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Metoclopramide Hydrochloride can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Antipsychotics (high‑potency D2 blockers): may potentiate extrapyramidal effects. - CYP2D6 substrates (e.g., codeine, tramadol): increased plasma levels and adverse effects.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, opioids): enhanced sedation and respiratory depression. - Anticholinergic agents: may reduce pro‑kinetic efficacy. - Digoxin: possible increase in serum concentrations. - Antihistamines: may augment drowsiness.